| Â | OS | PFS | LRFS | DMFS |
|---|
HR (95% Cl) | p | HR (95% Cl) | p | HR (95% Cl) | p | HR (95% Cl) | p |
|---|
Tumor stage* |  | 0.371 | – | – |  | 0.308 |  | 0.375 |
 II | 0.66 (0.27–1.64) |  |  |  | 0.63 (0.25–1.54) |  | 0.68 (0.30–1.58) |  |
 III + IV | Ref |  |  |  | Ref |  | Ref |  |
Groups |  | 0.002 |  |  < 0.001 |  | 0.001 |  |  < 0.001 |
 Group A | 2.80 (1.47–5.34) |  | 3.67 (2.09–6.46) |  | 2.82 (1.51–5.26) |  | 3.65 (1.96–6.78) |  |
 Group B | Ref |  | Ref |  | Ref |  | Ref |  |
- ALC: absolute lymphocyte count; CI, confidence interval; DMFS, distant metastasis-free survival; ECOG-PS: Eastern Cooperative Oncology Group performance status; HR: hazard ratio; LRFS, local recurrence-free survival; LRI, lymphocyte recovery index; OS, overall survival; PF: fluorouracil (5-FU) with cisplatin (DDP); PFS, progression-free survival; TC: PTX with carboplatin (CBP); TF: 5-FU with paclitaxel (PTX); TP: PTX with DDP
- *According to AJCC 6th. Group A included patients with G4 ALC nadir during dCCRT and LRI < 60% (N = 27) and group B with G4 ALC nadir during dCCRT and LRI ≥ 60% (N = 42)
